lobbying_activities: 1737199

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1737199	82670507-fcea-4733-83cc-bc98e74a9569	Q3	APOTEX CORP.	310973	APOTEX CORP.	2015	third_quarter	PHA	HR 6, The 21st Century Cures Act, provisions relating to the discovery, approval and manufacturing of pharmaceuticals; Federal policy relating to issues affecting the generic drug industry within the Senate Health, Education, Labor and Pensions Committee's Innovation for Healthier Americans initiative; HR 2841, The FAST Generics Act of 2015, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; S 1137, The FAIR Generics Act, provisions relating to market blockages caused by "parked" 180 day exclusivity periods; S. 2109, The Preserve Access to Affordable Generics Act, provisions relating to the legality of patent settlements between brand and generic pharmaceutical companies; Federal policy relating to the implementation of the Biologic Price Competition and Innovation Act, Title VII, Subtitle A, of Public Law 111-148, The Patient Protection and Affordable Care Act; and FDA proposed rule, Designation of Official Names for Certain Biological Products, Docket No. FDA-2015-N-0648, provisions related to nonproprietary naming for biologic products	HOUSE OF REPRESENTATIVES,SENATE		130000	0	0	2015-10-19T09:46:02.460000-04:00